Special Issue Title:

Novel precision medical models for breast cancer

Deadline for manuscript submissions: 31 July 2023

Print Special Issue Flyer (10)

Special Issue Editor

  • Guest Editor

    Xin Hua, MDE-MailWebsite

    Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

    Interests: Breast Cancer; Radiotherapy; Chemotherapy; Cancer Biomarker; Cancer Nutrition

  • Guest Editor

    Xing Niu, MDE-MailWebsite

    China Medical University, Shenyang, Liaoning, China

    Interests: Oncology; Molecular Biology; Bioinformatics; Pharmacology; Immunology; Genetics

Special Issue Information

Dear Colleagues,

Breast cancer is the most common malignancy worldwide and one of the leading causes of cancer-related death in women. The precision medical model for individual patients is the inevitable development trend of comprehensive treatment of breast cancer. The goal of precision medicine is to provide the right treatment to the right patient at the right time. One of its core principles is that cancer treatment needs to target the clinical and biological characteristics of individual. Therefore, besides the traditional prognostic factors, new clinical features and biomarkers are the focus of current research with the ultimate goal of improving the management and prognosis of breast cancer.

Currently, the general criteria for predicting prognosis and promoting stratification of treatment in breast cancer patients is the American Joint Committee on Cancer-Tumor, Node and Metastases (AJCC-TNM) stage system. This staging system focuses on tumor size and lymph node involvement without considering other prognostic factors (clinicalpathologic features, treatment-related factors, inflammatory status, etc.). As a result, breast cancer patients with similar stages tend to have very different survival outcomes. Therefore, more accurate methods are needed to improve the prognosis prediction of breast cancer patients. In recent years, gene expression characteristics such as 21-gene assay (Oncotype DX) and 70-gene signature (MammaPrint) have been increasingly used to provide prognostic information and to better select patients who might benefit from intensive treatment. It is important to explore novel and convenient tools that can effectively predict patient survival, so as to screen high-risk patients with poor prognosis and develop appropriate treatment plans.

Dr. Xin Hua and Dr. Xing Niu

Guest Editors


Breast Cancer; Precision Models; Biomarker; Treatment; Prognosis

Manuscript Submission Information

Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access journal published by MRE Press. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1200. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.

Share This Special Issue

Plan Papers (0 papers)

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time